靶向人Fcγ受体I的鼻内疫苗平台增强抗肺炎链球菌鼻咽定植能力并诱导针对呼吸道病原体的广谱保护性免疫
本研究评价hFcγRI靶向疫苗平台经鼻内与肌内免疫对黏膜免疫的影响。鼻内免疫PspA-FP在肺黏膜诱导的IgA、IgG和记忆T细胞反应显著高于肌内途径,两途径系统IgG反应相似。鼻内免疫抗肺炎链球菌鼻定植优于肌内免疫及肌内PspA-铝佐剂,且对土拉热弗朗西斯菌的保护与更优黏膜免疫相关。
要点
- 鼻内免疫PspA-FP的肺黏膜IgA、IgG和记忆T细胞反应显著高于肌内途径。
- 鼻内免疫抗肺炎链球菌鼻定植优于肌内免疫和肌内PspA-铝佐剂。
- hFcγRI靶向平台作为无佐剂黏膜疫苗对呼吸道病原体广谱有效。
核心结论
- hFcγRI靶向疫苗平台作为无佐剂黏膜疫苗对呼吸道病原体广谱有效。
- 对黏膜递送的保护需求因病原体类型而异。
研究设计与样本
- 临床前免疫原性与攻毒保护研究,比较鼻内与肌内免疫途径。
- 以肺炎链球菌PspA与hFcγRI靶向抗体融合蛋白PspA-FP为抗原。
- 以HA为抗原评价hFcγRI靶向疫苗对流感病毒的保护。
- 以土拉热弗朗西斯菌评价鼻内与肌内途径的保护差异。
主要发现
- 鼻内免疫PspA-FP在肺黏膜诱导的IgA、IgG和记忆T细胞反应显著高于肌内途径,两途径系统IgG反应相似升高。
- 鼻内免疫抗肺炎链球菌鼻定植优于肌内免疫,也优于肌内PspA-铝佐剂。
- 抗致死性肺炎链球菌肺部感染的保护与系统抗体反应相关,抗鼻定植与黏膜免疫反应相关。
- hFcγRI靶向HA疫苗经鼻内与肌内途径对肺部流感病毒感染保护相当。
- 鼻内途径抗致死性土拉热弗朗西斯菌肺部感染的保护优于肌内途径,与更优黏膜免疫反应相关。
关键数值与推荐
- 原文未报告具体数值、比例、阈值、剂量、样本量或P值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of safe and effective mucosal vaccines are hampered by safety concerns associated with adjuvants or live attenuated microbes. We previously demonstrated that targeting antigens to the human-Fc-gamma-receptor-I (hFcγRI) eliminates the need for adjuvants, thereby mitigating safety concerns associated with the mucosal delivery of adjuvant formulated vaccines. Here we evaluated the role of the route of immunization in the mucosal immunity elicited by the hFcγRI-targeted vaccine approach. To enable Ag targeting, PspA from Streptococcus pneumoniae (Sp) was genetically fused with the hFcγRI-targeting antibody (α-hFcγRI) to generate PspA-FP. Intranasal (IN) immunization with the PspA-FP induced significantly higher IgA, IgG, and memory T cell response in the lung mucosa compared to that of the intramuscular (IM) route, while both routes exhibited similar increase in the systemic IgG response. The IN immunization elicited better resistance against nasal colonization (NC) of Sp compared to the IM immunization. Additionally, the resistance to NC with the IN administered PspA-FP was higher than the PspA-Alum formulation administered by the IM route. While the protection form lethal pulmonary Sp infection correlated with the systemic Ab response, the resistance from NC (of Sp) correlated with the mucosal immune response. Similar to the pneumococcal pneumoniae model, the hFcγRI-targeted vaccine (based on HA as Ag) was equally protective against pulmonary Influenza virus infection via both routes. However, the IN route promoted better protection compared to the IM route against a lethal pulmonary infection with Francisella tularensis (Ft). The enhanced protection against Ft correlated with the superior mucosal immune response elicited by the IN route compared to the IM route. These observations showed a differential requirement for mucosal delivery for protection depending on the type of pathogen. Moreover, this study revealed that the hFcγRI-targeted vaccine platform is broadly-effective as an adjuvant-free mucosal vaccine platform against respiratory pathogens.
引用
- Kumar S, Hazlett K, Bai G, et al. Mucosal immunity elicited by a human-Fcγ receptor-I targeted intranasal vaccine platform enhances resistance against nasopharyngeal colonization of Streptococcus pneumoniae and induces broadly protective immunity against respiratory pathogens. Vaccine. 2025. PMID: 39823848. doi:10.1016/j.vaccine.2025.126729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。